Complete remission of primary cutaneous anaplastic large cell lymphoma after a short course of brentuximab vedotin

Milan,Elisa; Miceli,Paola; Sernicola,Alvise; Finotto,Silvia; Marino,Dario; Alaibac,Mauro

doi:10.3892/mco.2021.2283

June-2021 Volume 14 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

June-2021 Volume 14 Issue 6

Full Size Image

Article

Complete remission of primary cutaneous anaplastic large cell lymphoma after a short course of brentuximab vedotin

Authors:
- Elisa Milan
- Paola Miceli
- Alvise Sernicola
- Silvia Finotto
- Dario Marino
- Mauro Alaibac
View Affiliations / Copyright

Affiliations: Unit of Dermatology, University of Padua, Padova I‑35128, Italy, Unit of Medical Oncology 1, Veneto Institute of Oncology IOV‑IRCCS, Padova I‑35128, Italy
Article Number: 121
|
Published online on: April 15, 2021

https://doi.org/10.3892/mco.2021.2283
Expand metrics +

Abstract

Primary cutaneous anaplastic large cell lymphoma (PCALCL) is a rare CD30⁺ lymphoproliferative disorder characterized by the development of lesions ranging from papules to large tumors. Most cases present as localized disease, however multifocal and generalized involvement of the skin can occur. Several treatments have been proposed for PCALCL; however a highly effective standard approach to multifocal disease has not yet been elucidated. The disease expression of CD30 antigen in at least 75% of the tumor makes it an optimal target for immunotherapy. The current study presents a case of a 62‑year‑old male referred to the University of Padua Dermatology Clinic complaining about nodular and ulcerated lesions involving the frontal area and scalp that were 8 cm in diameter. Doses of 180 mg brentuximab vedotin (BV), which is an antibody drug conjugate binding CD30 antigen, were administered every 21 days. A 75% decrease in dimensions after the first infusion and a complete remission after the second was observed. Disease response appeared to be dose‑related and adverse reactions, in particular peripheral neuropathy, may be an effect of cumulative toxicity, meaning that treatment cycle reduction should be considered. Based on the present results, A high dose, short course of BV is recommended as a cost‑effective approach for PCALCL. However, further studies are required to assess the efficacy and other potential advantages of this therapeutic regimen.

View Figures

View References

1	Kempf W, Pfaltz K, Vermeer MH, Cozzio A, Ortiz-Romero PL, Bagot M, Olsen E, Kim YH, Dummer R, Pimpinelli N, et al: EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: Lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 118:4024–4035. 2011.PubMed/NCBI View Article : Google Scholar
2	Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S and Kim YH: Cd30⁺ cutaneous lymphoproliferative disorders: The stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol. 49:1049–1058. 2003.PubMed/NCBI View Article : Google Scholar
3	Shehan JM, Kalaaji AN, Markovic SN and Ahmed I: Management of multifocal primary cutaneous CD30⁺ anaplastic large cell lymphoma. J Am Acad Dermatol. 51:103–110. 2004.PubMed/NCBI View Article : Google Scholar
4	Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH and Jaffe ES: The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 133:1703–1714. 2019.PubMed/NCBI View Article : Google Scholar
5	Bekkenk MW, Geelen FA, van Voorst Vader PC, Heule F, Geerts ML, van Vloten WA, Meijer CJ and Willemze R: Primary and secondary cutaneous CD30(+) lymphoproliterative disorders: A report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 95:3653–3661. 2000.PubMed/NCBI
6	Artemi P, Wong D, Mann S and Regan W: CD30 (Ki-1)-positive primary cutaneous T-cell lymphoma: Report of spontaneous resolution. Australas J Dermatol. 38:206–208. 1997.PubMed/NCBI View Article : Google Scholar
7	Minich SS: Brentuximab vedotin: A new age in the treatment of hodgkin lymphoma and anaplastic large cell lymphoma. Ann Pharmacother. 46:377–383. 2012.PubMed/NCBI View Article : Google Scholar
8	Donato EM, Fernández-Zarzoso M, Hueso JA and de la Rubia J: Brentuximab vedotin in hodgkin lymphoma and anaplastic large-cell lymphoma: An evidence-based review. Onco Targets Ther. 11:4583–4590. 2018.PubMed/NCBI View Article : Google Scholar
9	Duvic M, Reddy SA, Pinter-Brown L, Korman NJ, Zic J, Kennedy DA, Lorenz J, Sievers EL and Kim YH: A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res. 15:6217–6224. 2009.PubMed/NCBI View Article : Google Scholar
10	Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, Han TH, Sievers EL and Bartlett NL: A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res. 18:248–255. 2012.PubMed/NCBI View Article : Google Scholar
11	Gravanis I, Tzogani K, van Hennik P, de Graeff P, Schmitt P, Mueller-Berghaus J, Salmonson T, Gisselbrecht C, Laane E, Bergmann L, et al: The European medicines agency review of brentuximab vedotin (Adcetris) for the treatment of adult patients with relapsed or refractory CD30⁺ hodgkin lymphoma or systemic anaplastic large cell lymphoma: Summary of the scientific assessment of the committee. Oncologist. 21:102–109. 2016.PubMed/NCBI View Article : Google Scholar
12	Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL and Forero-Torres A: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 363:1812–1821. 2010.PubMed/NCBI View Article : Google Scholar
13	Prince HM, Kim YH, Horwitz S, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, et al: Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): An international, open-label, randomised, phase 3, multicentre trial. Lancet. 390:555–566. 2017.PubMed/NCBI View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Complete remission of primary cutaneous anaplastic large cell lymphoma after a short course of brentuximab vedotin

This article is mentioned in:

Abstract

Figure 1

Related Articles